Achillion Pharmaceuticals

INVESTORS

Press Releases

 
Press Releases
  Date Title View
Apr 30, 2015
NEW HAVEN, Conn., April 30, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7, 2015 at...
PDF
Apr 25, 2015
- Two late breaker presentations detail previously announced 100% SVR12 in Phase 2 trial evaluating 6- or 8-weeks of treatment with ACH-3102 and sofosbuvir in genotype 1 HCV patients and Phase 1 proof-of-concept results with ACH-3422 -- Clinical virology presentation continues to support improved barrier to resistance with ACH-3102 - VIENNA, Au...
PDF
Apr 8, 2015
NEW HAVEN, Conn., April 8, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it will present three posters, including two late breaker abstracts, at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015. Poster presentations will i...
PDF
Mar 5, 2015
NEW HAVEN, Conn., March 5, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2014. For the three months ended December 31, 2014, the Company reported a net loss of $21.6 million, compared to a net loss of $13.4 million in the three months en...
PDF
Feb 18, 2015
NEW HAVEN, Conn., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the closing of its previously announced public offering of common stock. Achillion sold 13,800,000 shares of its common stock in the offering at a price to the public of $10.25 per share, including the exercise in full by the underwrite...
PDF
Feb 11, 2015
NEW HAVEN, Conn., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $10.25 per share. All of the shares in the offering will be sold by Achillion. The net proceeds to Achillion from the sa...
PDF
Feb 10, 2015
NEW HAVEN, Conn., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. In connection with this offering, Achillion plans to grant the underwriters a 30-day option to purchase additional shares of its common stoc...
PDF
Feb 9, 2015
- Achillion achieves 100% SVR12 in six-week regimen with combination of ACH-3102 and sofosbuvir for treatment-naïve genotype 1 HCV -- Achillion to initiate 4-week treatment regimens based on the strength of ACH-3102 antiviral data - NEW HAVEN, Conn., Feb. 9, 2015 (GLOBE NEWSWIRE) --Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announ...
PDF
Feb 6, 2015
NEW HAVEN, Conn., Feb. 6, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 8:55 a....
PDF
Dec 22, 2014
- A six-week dual NS5A - Nuc regimen of ACH-3102 and sofosbuvir was safe and well-tolerated with 100 percent SVR4 for treatment-naïve genotype 1 HCV ("Proxy Study")- ACH-3422 proof-of-concept trial showed it was safe and well-tolerated at doses of 50 mg-700 mg once daily achieving 4.8 log10 reduction with 700 mg dose after 14 days -- Conferenc...
PDF
FirstPrevious
...
7
...
NextLast